Next Article in Journal
Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus
Next Article in Special Issue
Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy
Previous Article in Journal
A Universal Influenza Virus Vaccine Candidate Tested in a Pig Vaccination-Infection Model in the Presence of Maternal Antibodies
Previous Article in Special Issue
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
Article Menu

Export Article

Open AccessReview
Vaccines 2018, 6(3), 65; https://doi.org/10.3390/vaccines6030065

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

1
Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen 6525 GA, The Netherlands
2
Laboratory of Experimental Hematology, University of Antwerp, Antwerp 2000, Belgium
3
Center for Oncological Research, University of Antwerp, Antwerp 2000, Belgium
4
Allergic Inflammation Discovery Performance Unit, Respiratory Therapy Area, GlaxoSmithKline, Stevenage SG1 2NY, UK
5
Department of Medical Oncology; Radboud Institute for Molecular Life Sciences, Radboudumc, Nijmegen 6525 GA, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 27 August 2018 / Revised: 17 September 2018 / Accepted: 18 September 2018 / Published: 19 September 2018
(This article belongs to the Special Issue Therapeutic Vaccines and Cancer Immunotherapy)
Full-Text   |   PDF [1365 KB, uploaded 19 September 2018]   |  

Abstract

Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in an antigen-specific manner systemically and at the tumor site. We hypothesize that BDCA1+CD14+ cells are present in a broad spectrum of cancers and demand further investigation to reveal treatment opportunities and/or improvement for DC vaccines. In this review, we summarize the findings on BDCA1+CD14+ cells in solid cancers. In addition, we evaluate the presence of BDCA1+CD14+ cells in leukemic cancers. Preliminary results suggest that the presence of BDCA1+CD14+ cells correlates with clinical features of acute and chronic myeloid leukemia. Future research focusing on the differentiation from monocytes towards BDCA1+CD14+ cells could reveal more about their cell biology and clinical significance. Targeting these cells in cancer patients may improve the outcome of cancer immunotherapy. View Full-Text
Keywords: BDCA1+CD14+ cells; cancer; dendritic cells; cancer immunotherapy; immune suppression; tumor microenvironment BDCA1+CD14+ cells; cancer; dendritic cells; cancer immunotherapy; immune suppression; tumor microenvironment
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Van Ee, T.J.; Van Acker, H.H.; Van Oorschot, T.G.; Van Tendeloo, V.F.; Smits, E.L.; Bakdash, G.; Schreibelt, G.; De Vries, I.J.M. BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target? Vaccines 2018, 6, 65.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top